Markets:

Overview

News

Currencies

International

Treasuries

Dyne Therapeutics, Inc. - Common Stock (NQ:DYN)

23.07 +1.28 (+5.87%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Dyne Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026? ↗

July 01, 2026

Dyne pursues rare disease breakthroughs while Vertex leverages blockbuster profits for pipeline expansion, how do their risk profiles and financials compare?

Via The Motley Fool

Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

June 26, 2026

Dyne is advancing therapies for rare muscle diseases while Viking targets the booming weight-loss market. See how their financials and risk profiles compare.

Via The Motley Fool

Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗

May 30, 2026

This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors.

Via The Motley Fool

Dyne Therapeutics Inc (NASDAQ:DYN) Reports Narrower-Than-Expected Q4 2025 Loss, Reaffirms Key Clinical Timelines ↗

March 02, 2026

Via Chartmill

Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis ↗

October 27, 2025

Via Stocktwits

Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗

May 30, 2026

Dyne Therapeutics targets rare muscle diseases with its FORCE platform, aiming to meet unmet needs in neuromuscular therapeutics.

Via The Motley Fool

Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗

May 19, 2026

This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Was Quietly Bought Before a $58 Per Share Takeout ↗

March 21, 2026

This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in active trials.

Via The Motley Fool

Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗

March 02, 2026

This clinical-stage biotech develops therapies for rare muscle diseases using its proprietary FORCE platform and research-driven approach.

Via The Motley Fool

Topics Regulatory Compliance

Why Dyne Therapeutics Stock Was a Big Winner on Wednesday ↗

December 10, 2025

The company is attracting much investor attention this week because of what happened in the lab.

Via The Motley Fool

Why Dyne Therapeutics Stock Tanked on Tuesday ↗

December 09, 2025

Investors were haunted by the specter of share dilution.

Via The Motley Fool

Biggest Market Movers Today, Dec. 9: WRBY, DYN, & More ↗

December 09, 2025

Stocks largely stayed in a holding pattern awaiting tomorrow's pronouncement from the Federal Reserve.

Via The Motley Fool

Topics Artificial Intelligence Bonds Economy

Dyne Therapeutics (DYN) Navigates a Paradoxical Day: Positive Clinical Data Overshadowed by Dilution Fears

December 09, 2025

New York, NY – December 9, 2025 – Dyne Therapeutics (NASDAQ: DYN) found itself in an unusual spotlight today, emerging as a significant market mover, albeit in a direction that belied ostensibly...

Via MarketMinute

This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? ↗

December 09, 2025

A late-stage biotech with three pivotal trials underway just landed a major hedge-fund backer — here’s why the timing matters.

Via The Motley Fool

Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow? ↗

December 09, 2025

Amylyx Stock is up a staggering 166% over the past year, and this biotech-focused hedge fund is still doubling down.

Via The Motley Fool

Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets ↗

December 09, 2025

A biotech specialist doubled down on Dyne ahead of a clinical readout that drew up investor fanfare — and the timing may be the entire story.

Via The Motley Fool

Topics Regulatory Compliance

Why Dyne Therapeutics Stock Was Blasting Higher Today ↗

December 08, 2025

The company reported solid progress with one of its investigational programs.

Via The Motley Fool

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗

December 03, 2025

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares?

Via The Motley Fool

Topics Regulatory Compliance

Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results

December 03, 2025

December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an...

Via MarketMinute

Why Dyne Therapeutics Stock Was Crushing it This Week ↗

November 21, 2025

The company has solid potential with its development of drugs targeting muscle disorders.

Via The Motley Fool

Topics Artificial Intelligence

Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday ↗

November 17, 2025

Via Benzinga

Why Dyne Therapeutics Stock Crushed the Market on Monday ↗

October 27, 2025

Biotechs like it are clearly valuable to strategic acquirers.

Via The Motley Fool

Which stocks are moving on Monday? ↗

October 27, 2025

Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Keep an eye on the top gainers and losers in Monday's session. ↗

October 27, 2025

Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 27, 2025

Via Benzinga

Janus Henderson, Avidity Biosciences, BridgeBio Pharma And Other Big Stocks Moving Higher On Monday ↗

October 27, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

October 27, 2025

Via Benzinga

Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket ↗

October 27, 2025

Via Benzinga

These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss ↗

July 29, 2025

Via Benzinga

Dyne Reports Wider Loss in Fiscal Q2 ↗

July 28, 2025

Via The Motley Fool

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.